BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), BioCryst (BCRX) a...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

Wedbush analyst Laura Chico maintained a Buy rating on BioCryst today and set a price target of $20.00. According to TipRanks, Chico is a 5-star an...

Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCryst (BCRX) and Damora Therapeutics (DMRA) with ...

Analysts’ Top Healthcare Picks: BioCryst (BCRX), Damora Therapeutics (DMRA)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on BioCryst today and set a price target of $15.00. Ahmad covers the Health...

BioCryst (BCRX) Receives a Buy from Bank of America Securities

In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00. Chico covers the Healthcar...

BioCryst (BCRX) Receives a Buy from Wedbush

BioCryst received a Hold rating and a $12.00 price target from J.P. Morgan analyst Jessica Fye today. According to TipRanks, Fye is a 5-star analys...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCRX	$9.38	+0.86%	4.38M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BCRX	$9.38	+0.9%	4.38M
3
4
5
6

BCRX

BCRX

Get BioCryst Pharmaceuticals, Inc. Data in Excel

Get BioCryst Pharmaceuticals, Inc. Data in Excel